The abstract is read at the publisher; the summary is JClub's.
In adults with newly diagnosed relapsing multiple sclerosis and recent disease activity, rituximab was noninferior to ocrelizumab for preventing new or enlarging T2 MRI lesions (92.2% vs 94.8%).
- Why it matters: Head-to-head evidence is lacking for anti-CD20 monoclonal antibodies in this setting, leaving uncertainty about comparative MRI suppression and safety profiles.
- What they did: In a phase 3, multicenter, double-blind noninferiority trial, adults were randomized 3:2 to rituximab or ocrelizumab every 6 months for 24 months, with T2 MRI lesion absence assessed from month 6 to month 24.
- The result: The risk difference for having no new or enlarging T2 lesions was -2.6 percentage points (95% CI, -9.4 to 4.3), meeting the noninferiority criterion; infections were more common with rituximab (82% vs 69%) while serious adverse events were similar (8% vs 7%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.